AllerVie Clinical Research
AllerVie Clinical Research
Birmingham, Alabama, United States14 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 2/3 Efficacy and Safety of PP405 in Adult Males | Pathological Conditions, Anatomical, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, alopecia, androgenetic alopecia, disorder of pilosebaceous unit, hypotrichosis, skin disorder | Recruiting | Phase 2 / Phase 3 | 2026-10-07 | NCT07819435 | |
| Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Mast Cell Activation Disorders, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, alpha-gal syndrome, autonomic nervous system disorder, bone marrow disorder, chronic myelomonocytic leukemia, connective tissue neoplasm, cutaneous mastocytosis, hematologic disorder, immune system disorder, leukemia, mastocytosis, myelodysplastic/myeloproliferative disease, myeloid leukemia, neoplasm, nervous system disorder, orthostatic intolerance, primary dysautonomia, skin disorder, skin neoplasm | Recruiting | Not stated | 2026-10-07 | NCT07143669 | |
| A Study of Lebrikizumab (LY3650150) in Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | Recruiting | Phase 3 | 2026-10-07 | NCT06338995 | |
| A 52-week Study of Remibrutinib in IgE-mediated Food Allergy | Cow's Milk Allergy, Egg Hypersensitivity, Hypersensitivity, Immediate, Milk Hypersensitivity, Nut and Peanut Hypersensitivity, Peanut Hypersensitivity, food allergy, immune system disorder | Recruiting | Phase 3 | 2026-09-25 | NCT07768371 | |
| A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines | Chronic Disease, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Recruiting | Phase 3 | 2026-09-25 | NCT06868212 | |
| A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Phase 2 | 2026-08-28 | NCT07599813 | |
| A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines | Chronic Disease, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic inducible urticaria, chronic urticaria, cold urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Active, not recruiting | Phase 3 | 2026-08-20 | NCT05976243 | |
| Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | Hypersensitivity, Immediate, Nut and Peanut Hypersensitivity, Peanut Hypersensitivity, allergic disease, food allergy, immune system disorder | Active, not recruiting | Phase 3 | 2026-07-22 | NCT07003919 | |
| Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) | Chronic Disease, Chronic Spontaneous Urticaria, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic inducible urticaria, chronic urticaria, cold urticaria, familial dermatographia, immune system disorder, skin disorder, skin vascular disease, urticaria | Active, not recruiting | Phase 2 | 2026-07-22 | NCT06931405 | |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma | Hypersensitivity, Immediate, Respiratory Hypersensitivity, asthma, bronchial disorder, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Active, not recruiting | Phase 2 | 2026-07-07 | NCT05851443 | |
| A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Recruiting | Phase 2 | 2026-05-04 | NCT05995964 | |
| An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib | Chronic Disease, Chronic Spontaneous Urticaria, Disease Attributes, Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, chronic urticaria, immune system disorder, skin disorder, skin vascular disease, urticaria | Active, not recruiting | Phase 3 | 2026-03-11 | NCT05513001 | |
| A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hereditary Complement Deficiency Diseases, Hypersensitivity, Immediate, Primary Immunodeficiency Diseases, Skin and Connective Tissue Diseases, angioedema, cardiovascular disorder, hereditary angioedema, hereditary disease, immune system disorder, inborn error of immunity, skin disorder, skin vascular disease, urticaria, vascular disorder | Active, not recruiting | Phase 2 | 2025-07-23 | NCT06007677 | |
| A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hereditary Complement Deficiency Diseases, Hypersensitivity, Immediate, Primary Immunodeficiency Diseases, Skin and Connective Tissue Diseases, angioedema, cardiovascular disorder, hereditary angioedema, hereditary disease, immune system disorder, inborn error of immunity, skin disorder, skin vascular disease, urticaria, vascular disorder | Active, not recruiting | Phase 1 / Phase 2 | 2024-05-16 | NCT05121376 |